Here are eight report highlights:
1. Implanet generated revenue of €4.094 thousand, representing a 24 percent increase from the same time period in 2015.
2. This revenue increase is due the boost in spine activity, which saw a 38 percent jump from the same time period the year prior.
3. The company upped its Jazz technological platform sales in the United States by 101 percent and in France by 40 percent, compared to the first half of 2015.
4. In the first half of 2016, providers used the Jazz technology in about 800 surgical interventions. Now, more than 2,800 patients have received treatment with the Jazz technology since its release in 2013.
5. Implanet’s knee segment saw a 12 percent increase in sales compared to the same period in 2015. The 50 percent growth in the French market accounts for this growth.
6. The company’s gross margin reached 52.5 percent of revenue, with reflects a 182 percentage point increase over 2015. This growth is due to the increase of U.S. Jazz sales.
7. Operating expenses increased by €302 thousand compared to the first half of 2015, due to the increase in U.S. sales and marketing costs.
8. Implanet reported cash and cash equivalents totaling €2 million and financial investments totaling €1.9 million.
Read the rest of the report, here.
More articles on devices:
Zimmer Biomet pledges $100k to OREF for orthopedic research: 5 key notes
SHS supports 3D-printing technology with investment in EIT Emerging Implant Technology: 4 things to know
6 market leaders drive anterior cervical fixation devices market — Globus Medical, J&J, Medtronic & more
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
